Immunologic response after 6 months of highly active antiretroviral therapy indicates a favorable clinical outcome in HIV-infected patients regardless of virologic response. This finding suggests that both immunologic and virologic markers should be used in clinical practice to evaluate treatment response.
Topics:
acquired immunodeficiency syndrome, antiretroviral therapy, highly active, protease inhibitor, treatment outcome, immunology, ...
Ann Intern Med. 2000;133(6):401-410. doi:10.7326/0003-4819-133-6-200009190-00007